Perspectives on cannabis as a substitute for opioid analgesics

被引:28
|
作者
Khan, Sara P. [1 ]
Pickens, Thomas A. [1 ]
Berlau, Daniel J. [1 ]
机构
[1] Regis Univ, Sch Pharm, Dept Pharmaceut Sci, 3333 Regis Blvd H-28, Denver, CO 80221 USA
关键词
analgesia; marijuana; mu-opioid receptor agonists; opioid-sparing effect; synthetic CB2 agonist; CROSS-SECTIONAL SURVEY; CANNOT TELL US; MEDICAL MARIJUANA; RECREATIONAL USERS; VAPORIZED CANNABIS; DRUG-INTERACTIONS; NEUROPATHIC PAIN; UNITED-STATES; THC; DELTA(9)-TETRAHYDROCANNABINOL;
D O I
10.2217/pmt-2018-0051
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
With the opioid epidemic reaching new heights in the USA, it has become critical to find suitable alternatives to opioids. Cannabis, an antinociceptive, is a strong contender to help patients reduce their opioid usage. A growing literature has been examining the complex effects cannabis has on pain relief and on opioid usage; whether it is a substitute for opioids or increases their use. This review explores the studies that compare cannabis-opioid interactions and presents some challenges of cannabis research and usage. The practical clinical pharmacology of cannabis as an analgesic, including the route of administration, safety and pharmacokinetics, are discussed to address the concerns, as well as possible solutions, of cannabis as a pain reliever.
引用
收藏
页码:191 / 203
页数:13
相关论文
共 50 条
  • [21] A national study on the use of opioid analgesics in dentistry
    Lino, Patricia Azevedo
    Sohn, Woosung
    Singhal, Astha
    Parreiras Martins, Maria Auxiliadora
    de Souza e Silva, Maria Elisa
    Nogueira Guimaraes de Abreu, Mauro Henrique
    BRAZILIAN ORAL RESEARCH, 2019, 33
  • [22] Encouraging disposal of unused opioid analgesics in Appalachia
    Helme, Donald W.
    Egan, Kathleen L.
    Lukacena, Kaylee M.
    Roberson, Lauren
    Zelaya, Carina Mazariegos
    McCleary, Monique Shauntelle
    Wolfson, Mark
    DRUGS-EDUCATION PREVENTION AND POLICY, 2020, 27 (05) : 407 - 415
  • [23] Drug interactions of opioid analgesics - weak opioids
    Kotlinska-Lemieszek, Aleksandra
    MEDYCYNA PALIATYWNA-PALLIATIVE MEDICINE, 2011, 3 (01): : 11 - 18
  • [24] Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls
    Reynaert, Marie-Line
    Dupoiron, Denis
    Yeramian, Edouard
    Marsollier, Laurent
    Brodin, Priscille
    TOXINS, 2019, 11 (09)
  • [25] Chronic pain patients' perspectives of medical cannabis
    Piper, Brian J.
    Beals, Monica L.
    Abess, Alexander T.
    Nichols, Stephanie D.
    Martin, Maurice W.
    Cobb, Catherine M.
    DeKeuster, Rebecca M.
    PAIN, 2017, 158 (07) : 1373 - 1379
  • [26] Rationale for cannabis-based interventions in the opioid overdose crisis
    Lucas, Philippe
    HARM REDUCTION JOURNAL, 2017, 14
  • [27] Cannabinoid concentrations in confiscated cannabis samples and in whole blood and urine after smoking CBD-rich cannabis as a "tobacco substitute"
    Hadener, Marianne
    Gelmi, Tim J.
    Martin-Fabritius, Marie
    Weinmann, Wolfgang
    Pfaffli, Matthias
    INTERNATIONAL JOURNAL OF LEGAL MEDICINE, 2019, 133 (03) : 821 - 832
  • [28] Opioid maintenance treatment and Cannabis use
    Schneider, Udo
    Schaefer, Ingo
    Hillemacher, Thomas
    Cimander, Konrad F.
    Wedekind, Dirk
    Weirich, Steffen
    Havemann-Reinecke, Ursula
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2019, 87 (10) : 548 - 553
  • [29] The effect of cannabis laws on opioid use
    Flexon, Jamie L.
    Stolzenberg, Lisa
    D'Alessio, Stewart J.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2019, 74 : 152 - 159
  • [30] Cannabis liberalisation and the US opioid crisis
    Imtiaz, Sameer
    Elton-Marshall, Tara
    Rehm, Jurgen
    BMJ-BRITISH MEDICAL JOURNAL, 2021, 372